Funding for this research was provided by:
University of Innsbruck and Medical University of Innsbruck
Article History
Received: 3 October 2023
Accepted: 4 January 2024
First Online: 25 January 2024
Conflict of interest
: B. Feroz reports travel expenses from Roche, Pfizer and Lilly. A. Zeimet reports consulting fees from Amgen, Astra Zeneca, GSK, MSD, Novartis, PharmaMar, Roche-Diagnostics, Seagen; honoraria from Amgen, Astra Zeneca, GSK, MSD, Novartis, PharmaMar, Roche, Seagen; travel expenses from Astra Zeneca, Gilead, Roche; participation on advisory boards from Amgen, Astra Zeneca, GSK, MSD, Novartis, Pfizer, PharmaMar, Roche, Seagen. C. Marth reports consulting fees from Roche, Novartis, Amgen, MSD, PharmaMar, Astra Zeneca, GSK, Seagen; honoraria from Roche, Novartis, Amgen, MSD, PharmaMar, Astra Zeneca, GSK, Seagen; travel expenses from Roche, Astra Zeneca; participation on advisory boards from Roche, Novartis, Amgen, MSD, Astra Zeneca, Pfizer, PharmaMar, GSK, Seagen. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.